Biocartis to present BRAF liquid biopsy data at ASCO

June 2, 2015 News BioVox

Biocartis (BCART), will today present liquid biopsy data from the BRAF mutation study at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study, in collaboration with Prof. Bart Neyns from the University Hospital Brussels, showed that BRAF oncogene mutations can be diagnosed not only in the solid tumor samples but also in plasma from metastatic melanoma patients.

Biocartis’ Idylla™ is a fully automated molecular diagnostic platform suited to work with virtually any clinical sample. In the presented study, Biocartis developed a prototype system for the analysis of BRAF mutations in circulating tumor DNA (ctDNA) from plasma samples. The system integrates and fully automates extraction of ctDNA and powerful selective amplification enabling the sensitive detection of BRAF V600 mutations from 1 ml of plasma.

Read more about Idylla™ and the use of liquid biopsies for diagnostics in our soon to be published interview with Prof. Bart Neyns.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter